2008 Lifetime Achievement Award in Heart Failure Presented During HFSA Annual Scientific Meeting



    
    Heart Failure Society of America Honors Michael R. Bristow, M.D., Ph.D.

    
    TORONTO, Sept. 22 /CNW/ -- The Heart Failure Society of America (HFSA)
announced today that Michael Bristow, M.D., Ph.D., Professor of Medicine
(Cardiology) and the Co-Director of the University of Colorado Cardiovascular
Institute, is the recipient of the Society's 2008 Lifetime Achievement Award.
The award was presented to Bristow at the Opening Plenary Session of the HFSA
12th Annual Scientific Meeting, Sept. 21-24, 2008 at the Metro Toronto
Convention Centre in Toronto, Ontario, Canada.
    "The HFSA's Lifetime Achievement Award is given each year to a clinician
or researcher who has advanced the awareness and treatment of heart failure
throughout their career," said Dr. Barry Greenberg, HFSA President, and
Professor of Medicine, and Director, Advanced Heart Failure Treatment Program,
University of California, San Diego. "Dr. Bristow has made many significant
contributions to the field of heart failure and we are honored to present him
with this award."
    Dr. Bristow received his MD in 1970 from the University of Illinois in
Chicago, where he also earned a PhD in pharmacology the following year.  After
completing an NIH postdoctoral fellowship in pharmacology at the University of
Illinois, he received his medical training at Stanford University, including
an internship in internal medicine, a research fellowship in
medicine/oncology, and a residency in medicine.  He remained at Stanford to
complete a fellowship in cardiology, where he joined the Cardiology faculty in
1979.  He moved to the University of Utah in 1984, where he co-founded the
first multi-hospital heart transplant program in the U.S.  Dr. Bristow is
board certified in internal medicine and in the subspecialty of cardiovascular
diseases.
    Dr. Bristow has authored more than 350 peer-reviewed papers and book
chapters on heart failure and other cardiovascular diseases. He was
instrumental in elucidating key molecular mechanisms underlying heart failure
and the use of beta-blockers for its treatment, and in developing the first
pharmacogenetically targeted cardiovascular drug (bucindolol, Gencaro(TM)),
currently under consideration for FDA approval.
    He has received many academic and industry honors, including the
Therapeutic Frontiers Award, presented by the American College of Clinical
Pharmacy, for development of beta-blockade as a treatment for chronic heart
failure, and in 2008 the Pharmaceutical Research and Manufacturers of America
Clinical Trial Exceptional Service Award for the development of carvedilol for
heart failure.  In 1999, he was ranked by Science Watch, as first among heart
failure investigators in impact of cardiovascular publications between 1993
and 1997, and he is an original member (2002) of the Institute of Scientific
Information's Highly Cited Researchers.
    The purpose of the HFSA Lifetime Achievement Award, to be given at the
HFSA Annual Scientific Meeting, is to recognize an individual who has made a
significant and sustained contribution to the field of heart failure in terms
of its scientific understanding, epidemiology or clinical care, or for his or
her exemplary leadership or inspiration to others resulting in an important
impact on the field.
    
    About Heart Failure
    
    Heart failure is a progressive condition in which the heart muscle
becomes weakened after it is injured from heart attack or high blood pressure
and gradually loses its ability to pump enough blood to supply the body's
needs. Many people are not aware they have heart failure because the symptoms
are often mistaken for signs of getting older. Heart failure affects from 4.6
to 4.8 million individuals in the United States. Demographic and clinical
evidence strongly suggest the prevalence of heart failure will increase
throughout the next decade. Ten to 15 years ago heart failure was considered a
"death sentence;" however, recent advances in treatment have shown that early
diagnosis and proper care in early stages of the condition are key to slowing,
stopping or in some cases reversing progression, improving quality of life,
and extending life expectancy. For more information on heart failure, please
visit www.abouthf.org.
    
    About the Heart Failure Society of America
    
    The Heart Failure Society of America (HFSA) is a nonprofit educational
organization, founded in 1994 as the first organized association of heart
failure experts. Today HFSA has over 1,700 members and provides a forum for
all those interested in heart function, heart failure research and patient
care. The Society also serves as a resource for governmental agencies (FDA,
NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight
recent advances in the development of strategies to address the complex
epidemiological, clinical and therapeutic issues of heart failure. Additional
information on HFSA can be found at www.hfsa.org.




For further information:

For further information: Kaitlyn Siner, +1-617-226-7192, cell,
+1-401-339-0954, ksiner@bellpottingerusa.com, or Ben Hendricks,
+1-617-226-7183, cell, +1-919-522-2978, bhendricks@bellpottingerusa.com, both
for The Heart Failure Society of America Web Site: http://www.hfsa.org

Organization Profile

THE HEART FAILURE SOCIETY OF AMERICA

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890